


Zhang Yi, founder of YS Biopharma, was elected as the member of the European Academy of Natural Sciences

BEIJING, CHINA, January 17, 2024

/EINPresswire.com/ -- Recently, Mr. Zhang Yi, the founder of YS Biopharma, was awarded and congratulated by Prof V.Tyminski, the Chairman of the Presidium of the European Academy of Natural Sciences (EANS), for his election of the EANS academician.

Mr. Zhang Yi, with more than 30 years of scientific research experience, has been engaged in global innovative drug development and management for over 20 years, and he has always been committed to the research and development of new biological

products. Under his leadership YS Biopharma has developed the world's first PIKA adjuvant technology platform with independent intellectual property rights, which has significant technical advantages in preventive vaccines, therapeutic vaccines and anti-tumor treatment. This may be the start of a new era for the vaccine research in the world: double effect of prevention and treatment. During this period, Mr. Zhang Yi presided over and participated in a number of major new drug projects under the leadership of the Ministry of Science and Technology. And he was the project leader of the national 863 scientific and technological research project "SARS immunoglobulin", the project leader of the national major new drug creation project "human PIKA rabies vaccine (Vero cells)", and the project leader of endogenous in vivo immune cell activation therapy anti-tumor drug Yivyka (Chinese name: 伊维卡; Code: YS-ON-001). Mr. Zhang Yi holds more than 20 invention patents such as the therapeutic PIKA Hepatitis B vaccine, the aluminum-free human rabies vaccine, the human rabies immunoglobulin. He was also awarded by numerous provincial and municipal science and technology achievement awards and honorary titles.



(Certificate of Mr Zhang Yi's election of the ENAS academician)

The European Academy of Natural Sciences, headquartered in Hannover, Germany, is one of the most recognized and influential international scientific organizations in the European academic

field. The Academy adopts a strict academician replacement system: before receiving the award medal, the elected academicians need to go through strict academic review and legal procedures such as academician recommendation, form review, defense review, voting election, presidium deliberation, notary impartiality. This selective procedure aims not only to examine the academic achievements, but also the creative contributions and influence of the candidates. As of today, the academy has more than 400 academicians, including more than 30 world famous science and technology award laureates, for instance, the Nobel Prize, the Einstein Prize, and the Copernicus Prize. Many Chinese academicians work as foreign members for the European Academy of Natural Sciences.

The academician qualification of the European Academy of Natural Sciences enjoys a very high reputation in the world. The European Academy of Natural Sciences represents the highest level of academia, and the academician qualification of the European Academy of Natural Sciences is not only the affirmation of the academic achievements of scholars, but also the recognition of their international influence and innovative spirit.

An Huijuan
YS Biopharma Co., Ltd.
[email us here](#)



This press release can be viewed online at: <https://www.einpresswire.com/article/681858244>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.